Existing partnerships
We partner with like-minded organizations to improve the lives of patients with chronic disease.
We work collaboratively with our partners to develop and create value added products for patients, health care professionals and health systems.
Partnership opportunities
Pharmanovia
Co-Development Partner
Pharmanovia is a global lifecycle management healthcare company. Pharmanovia and Closed Loop Medicine entered a co-development partnership to provide dose optimized personalized therapies, by combining Pharmanovia’s leading medicine brands with Closed Loop Medicine’s technology. The partnership will initially focus on the development of a drug + software combination product for the treatment of hypertension, before phased global roll-out and additional therapies are added.
Teva
Co-Development Partner
Teva Pharmaceuticals is a leading global provider of generic drugs and the largest supplier of medicines to the NHS. Teva UK and Closed Loop Medicine have partnered to advance the development of personalized medicines, by combining Teva’s pharmaceutical products with Closed Loop Medicine’s proprietary software as a medical device (SaMD) platform. The partnership will enable digital companions to be prescribed alongside traditional therapeutics to improve the effectiveness of both innovative and established medicines for specific chronic disorders.
NorthWest EHealth
Development partner
NorthWest EHealth are world leaders in the innovative and trustworthy use of routinely collected healthcare data for clinical trials. Closed Loop Medicine partnered with NorthWest EHealth for a retrospective real-world ethics-approved patient cohort study, a data extraction was undertaken from a proprietary 2.5m patient population in Greater Manchester. As well as the population level data analysis, health records of a subset of patients were analyzed to better understand constraints and logic in clinical care and decision making.
uMed
Development partner
uMed is a technology platform embedded within a global network of healthcare providers that automates the process of building high quality prospective research registries. Working with uMed, Closed Loop Medicine have been able to expand the reach and efficiency of a pivotal clinical study for patients with hypertension. The relationship embodies the future of how both clinical trials will be run and care delivered – decentralized.
Curebase
Development partner
CureBase has developed a full eClinical suite from the ground up, purpose-built for decentralized research. Closed Loop Medicine and Curebase partnered on the delivery of a decentralized clinical trial in the US during the COVID-19 pandemic for patients with hypertension.
The data generated from this study will be used to better understand the relationship between high blood pressure and COVID-19 as well as provide insights on disease management solutions.
Orient Pharma
Development partner
Orient Pharma is an R&D and manufacturing company based in Taiwan. Orient and Closed Loop Medicine have formed a strategic partnership for the development of novel drug + digital combination products. Orient Pharma are our key delivery partner in the development of the drug component of CLMIN01.
Innovate UK
Development partner
Innovate UK is part of UK Research and Innovation (UKRI) the national funding agency investing in science and research in the UK. Closed Loop Medicine secured multiple rounds of grant funding from Innovate UK through the Innovate UK Precision Medicine Innovation Accelerator to support clinical research in precision care solutions for high blood pressure.
Queen Mary University London, The William Harvey Research Institute – Barts and The London School of Medicine and Dentistry
Clinical Academic Partner
The William Harvey Research Institute is an internationally acknowledged center of excellence in the field of cardiovascular research. Together we are conducting a novel PhIV precision medicine interventional clinical trial for patients with high blood pressure. The clinical trial will see up to 1,000 patients recruited for a study investigating whether a combination product that links a drug to a smart phone app can enable patients to personalize and optimize their therapy regimen to treat hypertension.
We work collaboratively with our partners to develop and create value added products for patients, health care professionals and health systems.
Partnership opportunities
Pharmanovia
Co-Development Partner
Pharmanovia is a global lifecycle management healthcare company. Pharmanovia and Closed Loop Medicine entered a co-development partnership to provide dose optimized personalized therapies, by combining Pharmanovia’s leading medicine brands with Closed Loop Medicine’s technology. The partnership will initially focus on the development of a drug + software combination product for the treatment of hypertension, before phased global roll-out and additional therapies are added.
Teva
Co-Development Partner
Teva Pharmaceuticals is a leading global provider of generic drugs and the largest supplier of medicines to the NHS. Teva UK and Closed Loop Medicine have partnered to advance the development of personalized medicines, by combining Teva’s pharmaceutical products with Closed Loop Medicine’s proprietary software as a medical device (SaMD) platform. The partnership will enable digital companions to be prescribed alongside traditional therapeutics to improve the effectiveness of both innovative and established medicines for specific chronic disorders.
NorthWest EHealth
Development partner
NorthWest EHealth are world leaders in the innovative and trustworthy use of routinely collected healthcare data for clinical trials. Closed Loop Medicine partnered with NorthWest EHealth for a retrospective real-world ethics-approved patient cohort study, a data extraction was undertaken from a proprietary 2.5m patient population in Greater Manchester. As well as the population level data analysis, health records of a subset of patients were analyzed to better understand constraints and logic in clinical care and decision making.
uMed
Development partner
uMed is a technology platform embedded within a global network of healthcare providers that automates the process of building high quality prospective research registries. Working with uMed, Closed Loop Medicine have been able to expand the reach and efficiency of a pivotal clinical study for patients with hypertension. The relationship embodies the future of how both clinical trials will be run and care delivered – decentralized.
Curebase
Development partner
CureBase has developed a full eClinical suite from the ground up, purpose-built for decentralized research. Closed Loop Medicine and Curebase partnered on the delivery of a decentralized clinical trial in the US during the COVID-19 pandemic for patients with hypertension.
The data generated from this study will be used to better understand the relationship between high blood pressure and COVID-19 as well as provide insights on disease management solutions.
Orient Pharma
Development partner
Orient Pharma is an R&D and manufacturing company based in Taiwan. Orient and Closed Loop Medicine have formed a strategic partnership for the development of novel drug + digital combination products. Orient Pharma are our key delivery partner in the development of the drug component of CLMIN01.
Innovate UK
Development partner
Innovate UK is part of UK Research and Innovation (UKRI) the national funding agency investing in science and research in the UK. Closed Loop Medicine secured multiple rounds of grant funding from Innovate UK through the Innovate UK Precision Medicine Innovation Accelerator to support clinical research in precision care solutions for high blood pressure.
Queen Mary University London, The William Harvey Research Institute – Barts and The London School of Medicine and Dentistry
Clinical Academic Partner
The William Harvey Research Institute is an internationally acknowledged center of excellence in the field of cardiovascular research. Together we are conducting a novel PhIV precision medicine interventional clinical trial for patients with high blood pressure. The clinical trial will see up to 1,000 patients recruited for a study investigating whether a combination product that links a drug to a smart phone app can enable patients to personalize and optimize their therapy regimen to treat hypertension.
Latest news
Partner with us
Healthcare innovation requires partnership and collaboration centered on patients. Get in touch to find out more about how we create value for our partners.